BFS
CRNX

Bare Financial Services’s Crinetics Pharmaceuticals CRNX Stock Holding History

Bare Financial Services’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.05K Buy
28
+5
+22% +$186 ﹤0.01% 1360
2026
Q1 		$835 Sell
23
-24
-51% -$1.07K ﹤0.01% 1328
2025
Q4 		$2.19K Buy
+47
New +$2.09K ﹤0.01% 837
2025
Q3 		– Sell
-16
Closed -$460 – 1407
2025
Q2 		$460 Buy
+16
New +$494 ﹤0.01% 1160

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bare Financial Services's CRNX Position: Q2 2026 in Review

Bare Financial Services increased its Crinetics Pharmaceuticals (CRNX) stake by 22% in Q2 2026, buying an estimated $186 and bringing the position to 28 shares worth $1.05K. The position accounts for ﹤0.01% of the portfolio, ranked #1360.

Bare Financial Services first reported a position in CRNX in Q2 2025 and has held it in 4 quarters since. The position peaked at $2.19K in Q4 2025. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Bare Financial Services held 28 shares of Crinetics Pharmaceuticals worth $1.05K as of Q2 2026.
  • Bare Financial Services bought 5 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $186.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Bare Financial Services's portfolio in Q2 2026, its #1360 holding.
  • Bare Financial Services first reported a position in Crinetics Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • Bare Financial Services's Crinetics Pharmaceuticals position peaked at $2.19K in Q4 2025.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Bare Financial Services's 13F filing for Q2 2026, filed 27 Jul 2026.